Hydrogel T Cell Activation Bead Removal
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional ex-vivo T cell activation protocols using magnetic beads face challenges such as residual bead contamination, which affects cell viability and function, making it difficult to meet clinical specifications for T cell expansion and therapy applications.
Innovation Solution
A biocompatible hydrogel functionalized with T cell activating ligands that can be dissolved by a chelating agent, allowing for the separation of T cells from magnetic beads without affecting cell viability, and enabling consistent and reproducible activation of T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If magnetic beads are used for T cell activation and expansion, then T cell proliferation is enhanced, but residual bead contamination reduces cell viability and function
Solution Approach 1:
The invention divides the magnetic bead structure into two separate functional components: a magnetic separation unit and a cell activation unit. The magnetic beads are used solely for separation and do not remain in contact with cells during activation, eliminating contamination while maintaining both proliferation and viability benefits
Solution Approach 2:
The invention introduces an intermediary component (activation coating or soluble activators) that transfers the cell activation function from the magnetic beads to a separate entity. This intermediary mediates between the magnetic separation function and the T cell activation function, allowing beads to be removed before activation occurs
2Ease of operation
If conventional antibody-coated magnetic beads are used, then T cell activation is achieved, but bead release alters cell viability and phenotype
Solution Approach 1:
The invention separates the activation function from the magnetic bead structure, using either a removable activation coating or soluble activators. This segmentation allows activation to occur without magnetic beads present, preventing any bead-induced alterations to cell phenotype while maintaining activation efficacy
Solution Approach 2:
The invention employs disposable activation coatings or soluble activators that are used temporarily for activation and then discarded or degraded. These short-living activation agents perform their function and are removed, leaving no persistent contamination that could alter cell phenotype
3Productivity
If magnetic beads are retained in the final product, then cell expansion is maintained, but clinical specifications for purity are not met
Solution Approach 1:
The invention segments the magnetic bead system into a separate activation phase and a final product phase. During activation, magnetic beads or coatings are used to maintain cell expansion, but they are completely removed before the final product is prepared, ensuring clinical purity specifications are met while preserving expansion benefits
Solution Approach 2:
The invention extracts the magnetic bead component from the final cell product. Magnetic beads are used during the activation and expansion process but are completely removed through washing and separation steps before the final T cell product is prepared for clinical use, ensuring no bead contamination remains
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hydrogel-based method effectively removes residual beads, enhancing T cell viability and function, allowing for higher proportions of desired T cell subsets like CD8+ cells and naïve T cells, while maintaining cell phenotype and reducing host response, thus improving the clinical applicability of T cell therapies.
Implementation Method 1
the polymer that changes from a solid matrix into a solution or suspension in response to decrease in cationic concentration (e.g., Li+, Mg2+, Ca2+, Sr2+, Ba2+, Zn2+, Cu2+, or Al3+) caused by the presence of an ion chelator (e.g., EDTA, EGTA, sodium citrate, BAPTA, crown ether, cryptand, phenanthroline sulfonate, dipyridyl sulfonate, dioxane, DME, diglyme, or triglyme)
Implementation Method 2
a unique hydrogel that is biocompatible, functionalized with T cell activating ligands such as antibodies, and can be dissolved rapidly simply by switching to a buffer containing a chelating agent
Implementation Method 3
the separation unit dissociates from the binding unit upon exposure of the polymeric moiety to an ion chelator
Implementation Method 4
a complex including a binding unit, i.e., hydrogel, and a separation unit, e.g., magnetic beads
Data Source
AI summary
The invention features a complex that binds to, stimulates, and expands a desired T cell population and facilitates separation of the target population from a sample. The complex can be gently dissociated from the binding unit after separating the desired T cell population, representing a safe and efficient approach for processing T cells for clinical use. Invention also provides methods of using such complexes as part of adoptive T cell therapy systems.